Online first
Research paper
Published online: 2024-04-18

open access

Page views 208
Article views/downloads 189
Get Citation

Connect on Social Media

Connect on Social Media

Association between serum levels of calcium, magnesium, iron and copper and insulin resistance in women with full blown and not-full blown phenotypes of polycystic ovary syndrome

Katarzyna Skrypnik1, Dagmara Pluta2, Mariusz Wojtowicz3, Tahar Ben Rhaiem4, Joanna Suliburska5

Abstract

The aim of present study was to investigate the association between serum calcium, iron, magnesium, copper levels and insulin resistance in women with full blown phenotype of polycystic ovary syndrome (PCOS) compared to women with not-full blown phenotype.
104 women, aged 18–39, in the first phase of menstrual cycle, diagnosed with PCOS based on the Rotterdam Criteria, were qualified for the study. Patients were divided into two groups: group I contained women with full blown PCOS (phenotype A) and group II contained women with not-full blown PCOS (phenotypes B, C and D). Whole study population was divided on group X containing women with proper insulin sensitivity and group Y containing women with insulin resistance. The study found that women with full blown PCOS had lower level of magnesium compared with not-full blown phenotypes. Also, the level of copper was lower in group with proper insulin sensitivity compared to group with insulin resistance. Serum cooper content showed a negative correlation with Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) in group with full blown phenotype. Magnesium level showed positive correlation with level of calcium and cooper in group with proper insulin sensitivity. Level of iron content showed a negative correlation with sex hormone binding globulin (SHBG) and HOMA-IR showed a positive correlation with age and body mass index (BMI) in group with insulin resistance. Either level of calcium showed positive correlation with iron and cooper in group with insulin resistance.

Article available in PDF format

View PDF Download PDF file

References

  1. Mathew M, Sivaprakasam S, Phy JL, et al. Polycystic ovary syndrome and iron overload: biochemical link and underlying mechanisms with potential novel therapeutic avenues. Biosci Rep. 2023; 43(1).
  2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1): 19–25.
  3. Sachdeva G, Gainder S, Suri V, et al. Comparison of the Different PCOS Phenotypes Based on Clinical Metabolic, and Hormonal Profile, and their Response to Clomiphene. Indian J Endocrinol Metab. 2019; 23(3): 326–331.
  4. Jabeen A, Yamini V, Rahman Amberina A, et al. Polycystic Ovarian Syndrome: Prevalence, Predisposing Factors, and Awareness Among Adolescent and Young Girls of South India. Cureus. 2022; 14(8): e27943.
  5. Zhao H, Zhang J, Cheng X, et al. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. J Ovarian Res. 2023; 16(1): 9.
  6. Mahmoudi T, Gourabi H, Ashrafi M, et al. Calciotropic hormones, insulin resistance, and the polycystic ovary syndrome. Fertil Steril. 2010; 93(4): 1208–1214.
  7. Gembillo G, Labbozzetta V, Giuffrida AE, et al. Potential Role of Copper in Diabetes and Diabetic Kidney Disease. Metabolites. 2022; 13(1).
  8. Aigner E, Felder TK, Oberkofler H, et al. Glucose acts as a regulator of serum iron by increasing serum hepcidin concentrations. J Nutr Biochem. 2013; 24(1): 112–117.
  9. Sun G, Vasdev S, Martin GR, et al. Altered calcium homeostasis is correlated with abnormalities of fasting serum glucose, insulin resistance, and beta-cell function in the Newfoundland population. Diabetes. 2005; 54(11): 3336–3339.
  10. Chakraborty P, Ghosh S, Goswami SK, et al. Altered trace mineral milieu might play an aetiological role in the pathogenesis of polycystic ovary syndrome. Biol Trace Elem Res. 2013; 152(1): 9–15.
  11. Diamanti-Kandarakis E, Livadas S, Katsikis I, et al. Serum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic ovarian syndrome. J Bone Miner Metab. 2011; 29(2): 201–206.
  12. Fillebeen C, Lam NH, Chow S, et al. Regulatory Connections between Iron and Glucose Metabolism. Int J Mol Sci. 2020; 21(20).
  13. Shu T, Lv Z, Xie Y, et al. Hepcidin as a key iron regulator mediates glucotoxicity-induced pancreatic β-cell dysfunction. Endocr Connect. 2019; 8(3): 150–161.
  14. Zheng R, Lin C, Mao Y, et al. miR-761-hepcidin/Gpx4 pathway contribute to unexplained liver dysfunction in polycystic ovary syndrome by regulating liver iron overload and ferroptosis. Gynecol Endocrinol. 2023; 39(1): 2166483.
  15. Oost LJ, Kurstjens S, Ma C, et al. Magnesium increases insulin-dependent glucose uptake in adipocytes. Front Endocrinol (Lausanne). 2022; 13: 986616.
  16. Sharifi F, Mazloomi S, Hajihosseini R, et al. Serum magnesium concentrations in polycystic ovary syndrome and its association with insulin resistance. Gynecol Endocrinol. 2012; 28(1): 7–11.
  17. Kant R, Verma V, Patel S, et al. Effect of serum zinc and copper levels on insulin secretion, insulin resistance and pancreatic β cell dysfunction in US adults: Findings from the National Health and Nutrition Examination Survey (NHANES) 2011-2012. Diabetes Res Clin Pract. 2021; 172: 108627.
  18. Raudenska M, Dvorakova V, Pacal L, et al. Levels of heavy metals and their binding protein metallothionein in type 2 diabetics with kidney disease. J Biochem Mol Toxicol. 2017; 31(6).
  19. Naka T, Kaneto H, Katakami N, et al. Association of serum copper levels and glycemic control in patients with type 2 diabetes. Endocr J. 2013; 60(3): 393–396.
  20. Sonkar SK, Parmar KS, Ahmad MK, et al. An observational study to estimate the level of essential trace elements and its implications in type 2 diabetes mellitus patients. J Family Med Prim Care. 2021; 10(7): 2594–2599.
  21. Jiang Q, Zhang F, Han L, et al. Serum Copper Level and Polycystic Ovarian Syndrome: A Meta-Analysis. Gynecol Obstet Invest. 2021; 86(3): 239–246.
  22. Kirmizi DA, Baser E, Turksoy VA, et al. Are Heavy Metal Exposure and Trace Element Levels Related to Metabolic and Endocrine Problems in Polycystic Ovary Syndrome? Biol Trace Elem Res. 2020; 198(1): 77–86.
  23. Marshall JC, Dunaif A. Should all women with PCOS be treated for insulin resistance? Fertil Steril. 2012; 97(1): 18–22.
  24. Panidis D, Tziomalos K, Misichronis G, et al. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod. 2012; 27(2): 541–549.
  25. Liu C, Liu K, Zhao X, et al. The Associations Between Alanine Aminotransferase and Other Biochemical Parameters in Lean PCOS. Reprod Sci. 2023; 30(2): 633–641.
  26. Livadas S, Bothou C, Kuliczkowska-Płaksej J, et al. Can dysglycemia in OGTT be predicted by baseline parameters in patients with PCOS? Endocr Connect. 2022; 11(4).
  27. Sachdeva G, Gainder S, Suri V, et al. Comparison of the Different PCOS Phenotypes Based on Clinical Metabolic, and Hormonal Profile, and their Response to Clomiphene. Indian J Endocrinol Metab. 2019; 23(3): 326–331.
  28. Rudnicka E, Suchta K, Grymowicz M, et al. Chronic Low Grade Inflammation in Pathogenesis of PCOS. Int J Mol Sci. 2021; 22(7).
  29. Li R, Li Z, Huang Yi, et al. The effect of magnesium alone or its combination with other supplements on the markers of inflammation, OS and metabolism in women with polycystic ovarian syndrome (PCOS): A systematic review. Front Endocrinol (Lausanne). 2022; 13: 974042.
  30. Pokorska-Niewiada K, Brodowska A, Szczuko M. The Content of Minerals in the PCOS Group and the Correlation with the Parameters of Metabolism. Nutrients. 2021; 13(7).
  31. Проданчук МГ, Татарчук ТФ, Гуньков СВ, et al. The role of macro- and microelements in the pathogenesis of polycystic ovary. Reproductive Endocrinology. 2019; 0(48): 22–25.
  32. Hestiantoro A, Astuti BP, Joyo EO, et al. Vitamin B (niacin), B, C, and iron intake are associated with the free androgen index, especially in normoandrogenic polycystic ovary syndrome. J Turk Ger Gynecol Assoc. 2022; 23(3): 130–136.
  33. Pluta D, Franik G, Blukacz Ł, et al. The correlation between the concentration of hepcidin in serum and the occurrence of insulin resistance and hyperandrogenemia in women with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2018; 22(21): 7379–7384.
  34. Alesi S, Ee C, Moran LJ, et al. Nutritional Supplements and Complementary Therapies in Polycystic Ovary Syndrome. Adv Nutr. 2022; 13(4): 1243–1266.